{"id":"hydroxychloroquine-low-dose-prednisone","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Retinopathy (hydroxychloroquine)"},{"rate":null,"effect":"Immunosuppression-related infections"},{"rate":null,"effect":"Osteoporosis (prednisone)"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydroxychloroquine is an antimalarial agent that accumulates in lysosomes and inhibits toll-like receptor signaling and antigen presentation, reducing T-cell and B-cell activation. Low-dose prednisone, a corticosteroid, suppresses inflammatory cytokine production and immune cell proliferation. Together, this combination targets multiple pathways in autoimmune and inflammatory diseases.","oneSentence":"Hydroxychloroquine suppresses immune activation and inflammatory responses, while low-dose prednisone provides additional anti-inflammatory and immunosuppressive effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:55:16.035Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic lupus erythematosus (SLE)"},{"name":"Rheumatoid arthritis"},{"name":"Other autoimmune or inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT05714670","phase":"PHASE2","title":"The Effect of Curcumin on the Clinical Outcome of Pediatric Patients with Active Lupus Nephritis","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-04-01","conditions":"Lupus Nephritis, SLE Nephritis","enrollment":72},{"nctId":"NCT05247554","phase":"PHASE3","title":"Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-03-01","conditions":"Pulmonary Sarcoidosis","enrollment":200},{"nctId":"NCT04380818","phase":"NA","title":"Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19","status":"UNKNOWN","sponsor":"Grupo de Investigación Clínica en Oncología Radioterapia","startDate":"2020-06-05","conditions":"Pneumonia, Viral","enrollment":106},{"nctId":"NCT03671174","phase":"NA","title":"Immunosuppressant Regimens for Living Fetuses Study","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2019-08-02","conditions":"Undifferentiated Connective Tissue Disease, Recurrent Pregnancy Loss","enrollment":420}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Experimental Arm"],"phase":"phase_3","status":"active","brandName":"Hydroxychloroquine + low-dose prednisone","genericName":"Hydroxychloroquine + low-dose prednisone","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydroxychloroquine suppresses immune activation and inflammatory responses, while low-dose prednisone provides additional anti-inflammatory and immunosuppressive effects. Used for Systemic lupus erythematosus (SLE), Rheumatoid arthritis, Other autoimmune or inflammatory conditions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}